Knopp Neurosciences deal shows how IP strategy can build value for licensing

In a deal spotlighting the value that can be created when a strong research team implements a strategic intellectual property protection plan, Pittsburgh-based Knopp Neurosciences, Inc. recently signed an agreement worth $80 million in which Knopp and Biogen, Inc. will develop and commercialize KNS-760704 (dexpramipexole) for the treatment of amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease.

My colleagues Ray Miller and Nicole Endejann of Pepper Hamilton LLP worked with Knopp to develop the intellectual property rights for the drug.  According to a press release announcing the deal: 

Miller and Endejann, along with other Pepper Hamilton colleagues, developed an exclusivity strategy for Knopp Neurosciences discoveries that included strategic patent protection, while also negotiating the layering of potential marketing exclusivities provided by regulatory authorities, such as orphan drug designation.

 For more details about the transaction, click here and here.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s